Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.

Aya NakayaTakayasu KurataHiroshige YoshiokaYuki TakeyasuMaiko NikiKayoko KibataNaoko SatsutaniMakoto OgataTakayuki MiyaraShosaku Nomura

Published in: International journal of clinical oncology (2018)

The NLR at 2 and 4 weeks after treatment might be a useful marker for the prediction of the treatment response or disease progression in patients with advanced NSCLC receiving nivolumab.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
small cell lung cancer
tyrosine kinase
gestational age
metabolic syndrome
type diabetes
insulin resistance
skeletal muscle
weight loss